FMP
eFFECTOR Therapeutics, Inc.
EFTR
NASDAQ
eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer. The company is also developing Zotatifin, a small molecule designed to inhibit eukaryotic initiation factor 4A (eIF4E), which is in phase 2clinical trial to treat patients with solid tumors. It has a collaboration agreement with Pfizer Inc. to develop inhibitors of eIF4E. eFFECTOR Therapeutics, Inc. was founded in 2012 and is headquartered in Solana Beach, California.
1.78 USD
-0.11 (-6.18%)
About
ceo
Dr. Stephen T. Worland Ph.D.
sector
Healthcare
industry
Biotechnology
website
https://effector.com
exchange
NASDAQ
Description
eFFECTOR Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of selective translation regulator inhibitors for the treatment of cancer. Its lead product candidate is Tomivosertib, an oral small-molecule inhibitor of MNK that is in phase 2b clinical trial for the treatment of patients with metastatic non-small cell lung cancer. The company is also developing Zotatifin, a small molecule designed to inhibit eukaryotic initiation factor 4A (eIF4E), which is in phase 2clinical trial to treat patients with solid tumors. It has a collaboration agreement with Pfizer Inc. to develop inhibitors of eIF4E. eFFECTOR Therapeutics, Inc. was founded in 2012 and is head...
CIK
0001828522
ISIN
US28202V2079
CUSIP
28202V108
Address
142 North Cedros Avenue
Phone
858 925 8215
Country
US
Employee
14
IPO Date
Mar 1, 2021
Summary
CIK
0001828522
Exchange
NASDAQ
Industry
Biotechnology
Sector
Healthcare
CUSIP
28202V108
ISIN
US28202V2079
Country
US
Price
1.78
Beta
0.52
Volume Avg.
381.37k
Market Cap
6.56M
Shares
-
52-Week
1.75-37.0
DCF
-2.09
ROE
-
ROA
-
Operating Margin
-
Debt/Equity
-
P/E
-0.11
P/B
-
Website
https://effector.com
Historical Prices
We are unable to load the chart at this time.
Financial Statement
We are unable to load the chart at this time.
Earnings
We are unable to load the chart at this time.
Upgrades and Downgrades
We are unable to load this data!
People Also Watch
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
Latest EFTR News
It looks like there's no news available.
